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iomarker Bonanza?*
obert M. Califf, MD,†
vati H. Shah, MD, MHS,‡
. Kristin Newby, MD, MHS‡
urham, North Carolina
n this issue of the Journal, Morrow et al. (1) from the TIMI
roup, provide a provocative update of the MERLIN–TIMI
6 (Metabolic Efficiency With Ranolazine for Less Ischemia
n Non-ST Elevation Acute Coronary–Thrombolysis In Myo-
ardial Infarction 36) trial. Their report raises the possibility
hat a single measurement of plasma concentrations of B-type
atriuretic peptide (BNP), taken early in the hospital course of
atients with acute coronary syndrome (ACS), not only can
dentify a cohort at higher risk of poor clinical outcomes, but
ay also differentiate patients more likely to experience a
eduction in recurrent cardiac events with ranolazine from
hose who would not benefit from ranolazine.
See page 1189
Studies such as this represent an attempt to break a path
nto the relatively uncharted territory of “personalized med-
cine” (2). Although the term has different meanings for
ifferent people, most “sales pitches” for personalized med-
cine allude to the incorporation of biomarkers into clinical
esearch and practice, a practice that promises to distinguish
hose who will benefit from a proposed treatment from those
ho will not (or who may even be harmed). Because this practice
ivides populations into strata, we prefer the term stratified medi-
ine, in which the personalized component revolves around the
nclusion of the patient’s desires and values when making choices
bout medical care.
A biomarker is defined as a characteristic that is objec-
ively measured and evaluated as an indicator of normal
iological processes, pathogenic processes, or pharmacologic
esponses to a therapeutic intervention (3). Biomarkers have
ultiple uses in the arenas of research and practice. In the
evelopment of medical technologies, biomarkers can be
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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eartscapt Technologies, Mosby, Roche Diagnostics, Schering-Plough, and Scios.sed to identify preclinical models and human subjects with
pathophysiology of interest and to assess the effects of an
ntervention on both on- and off-target biological systems.
n clinical practice, a biomarker may be used to diagnose a
edical problem, serve as a tool for staging disease, or
rovide an indicator of differential prognosis (4). As noted
arlier, biomarkers become especially powerful when they
llow the identification and stratification of patients into
ubpopulations who will derive more or less benefit from an
ntervention (5). Under such circumstances, biomarkers can
e used to predict or monitor response to a treatment.
A particularly cherished pipe dream of many involved in
he development of medical therapeutics is one in which
umerous biomarkers can be pressed into service as surro-
ate end points. Despite well-written treatises underscoring
he shortcomings of this concept (6), it has proven difficult
o convey the notion that only a very few biomarkers will
ctually be established as useful and valid surrogates for
herapeutic benefit. Patients and their families care about
linical end points, which are measures of how a person
eels, functions, or survives. A biomarker, however, ap-
roaches true surrogate status only when a change in the
iomarker (the putative surrogate) attributable to an inter-
ention approximates a complete prediction of the change in
he clinical end point, a circumstance that rarely, if ever,
ccurs. Further, a treatment ultimately should be recom-
ended on the basis of the net balance of benefits and risks
n light of all possible clinical outcomes, but a perfect
iomarker for a particular clinical end point cannot possibly
e informative about all other outcomes of interest.
Additionally, the promise that deploying biomarkers in
linical trials would reduce the number of subjects needed
as proven illusory. It is true that individual trials may be
onducted with smaller numbers of subjects if the target
opulation can be identified before the experiment. For
xample, if a biomarker is thought to predict a major
ifferential benefit from treatment, then by preferentially
nrolling patients on the basis of levels of that biomarker,
uch benefit may be shown in a smaller study population.
everal important caveats apply, however. First, the benefit
an be claimed specifically for biomarker-positive patients
nly if biomarker-negative patients are also studied, so that
he contrast in benefit-risk balance is proven. Second, when
oth biomarker-positive and biomarker-negative patients
re studied, the difference in treatment effect is typically not
all or nothing.” We are then obliged to conduct a series of
tudies to determine whether a particular subpopulation (or
ultiple subpopulations) exhibits a benefit-risk balance that
ustifies giving or withholding treatment on a more contin-
ous scale. Finally, identifying a subpopulation that derives
ifferential benefit implies that those who do not benefit
arrant further evaluation, if effective therapies are to be
eveloped for that group. When all these caveats are taken
nto account, the total number of subjects needed for clinical
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Biomarker Bonanza? March 23, 2010:1197–9rials is likely not only to increase, but perhaps to increase by
s much as a log order!
The developmental pathway for biomarkers intended for
se in clinical research or practice is equally complex. Some
ave proposed that we should apply a structured conceptual
ramework to the development of useful biomarkers. For
nstance, one notion that has proved enticing is that, as is
he case in drug development, researchers could move from a
undamental discovery science mode to development of biomar-
ers in nonhuman models, then into early-phase human studies
which might include both intensive small-scale and epidemio-
ogical studies), eventually to be followed by confirmatory studies.
Although such a linear approach is satisfying to the
rderly mind, several major trends have turned this neatly
ompartmentalized world on its head. First, we have come
o recognize that human biology cannot be reduced to a
eries of linear mechanisms; rather, it comprises a vast
etwork of interwoven pathways and systems. This recog-
ition has led to the concept of systems biology, which is
uilt in part on the assumption that much future discovery
ill depend on mathematical constructs that elucidate the
arious relationships among multiple pathways, an enter-
rise that requires the study of higher-order systems (e.g.,
ntact animals and people).
Second, modern technology now allows us to measure
enes, gene expression, proteins, and metabolites in human
opulations in great detail using unbiased discovery plat-
orms. Such unbiased analyses will inevitably lead to the
dentification of many genes, proteins, and metabolites, the
xact biological functions of which are currently unknown.
ndeed, when biomarkers are used for clinical prediction of
rognosis or treatment response, it is not necessary to
nderstand their underlying biology (although such under-
tanding would always be preferable) because their associa-
ion with disease, adverse prognosis, or response to therapy
ill provide clues about new therapies and biomarkers (7).
n such an environment, the fluid interplay between classical
echanistic biology, systems discovery, and clinical appli-
ation becomes crucial.
Third, we continue to struggle with the complexity of
uman decision making. A question that appears to be
imple on the surface—if a patient has ACS and a high
NP level, should we use ranolazine?—becomes dauntingly
omplex when an array of related information about con-
omitant treatments, patient preferences, and heuristics
omes into play (8). All of these complexities and uncer-
ainties boil down to a binary decision: to treat or not to
reat. The need to distill simple decision rules, however,
ust not dissuade us from elucidating the full complexity of
iomarkers during the research phase.
Where does the current report by Morrow et al. (1) fall on
his spectrum of thinking? The authors carefully collected
amples in the context of a randomized clinical trial and
nalyzed BNP concentrations in light of an a priori hypoth-
sis that ranolazine may have a specific effect on wall stress
n the myocardium and that patients with higher wall stresss measured by BNP might benefit preferentially from
reatment. The authors’ previous work suggesting that BNP
easurement identifies a high-risk population of ACS
atients was confirmed. More exciting, however, was the
nding (supported by a rigorous test for interaction between
reatment assignment and BNP level), that ranolazine
educed the risk of poor outcomes in subjects with a BNP
80 pg/ml, but not in subjects with lower BNP concentra-
ions. The authors appropriately note that the overall trial showed
o significant reduction in cardiovascular events with ranolazine;
herefore, technically, the test for a differential benefit as a function
f BNP concentration could not be conducted while maintaining
measurable false-positive rate.
Although this report does not provide definitive evidence
hat ranolazine should be used in patients with ACS and
levated BNP levels, it nonetheless represents a carefully
onducted study with findings that are sufficiently persuasive
o warrant a prospective clinical trial. Concomitantly, sev-
ral other issues raised by this report deserve consideration
n the context of studies evaluating the role of biomarkers as
linical tools. First, the specific role of BNP measurement in
he setting of ACS could best be defined by an exploration
f the likelihood of events and treatment effect as a function of
he continuous measurement of BNP, rather than settling on a
inary cut point too early in the exploration phase. In this case,
BNP threshold level of 80 pg/ml may be optimal for
iscriminating risk of death or heart failure, although the
uthors did not display the raw or modeled data that would
llow readers to judge the appropriateness of the cutoff. The
ptimal threshold for treatment benefit with ranolazine may
lso be different. In addition, given the biological complexity of
CS and related downstream clinical events, the appropriate
lace of BNP measurement in a “multimarker strategy” needs
o be defined. Finally, the ultimate test of the utility of BNP,
s for any biomarker, would be to randomly assign patients to
ave the biomarker measured or not, with subsequent phar-
acological therapy with ranolazine determined by BNP levels
n the biomarker arm and with clinical outcome as the
ependent variable. The TIMI investigators have made signif-
cant strides toward the biomarker bonanza, but much work
emains before we can reap the rewards.
eprint requests and correspondence: Dr. Robert M. Califf,
uke Translational Medicine Institute, Duke University Medical
enter, DUMC Campus Box 3850, Durham, North Carolina
7710. E-mail: robert.califf@duke.edu.
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